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B-Type Natriuretic Peptide Concentrations Predict
the Progression of Nondiabetic Chronic Kidney
Disease: The Mild-to-Moderate Kidney
Disease Study
Katharina-Susanne Spanaus,1 Florian Kronenberg,2 Eberhard Ritz,3
Ralph Schlapbach,4 Danilo Fliser,5 Martin Hersberger,1 Barbara Kollerits,2
Paul Ko¨nig,6 and Arnold von Eckardstein1* for the Mild-to-Moderate
Kidney Disease Study Group
Background: Plasma concentrations of B-type natri-
uretic peptide (BNP) and N-terminal proBNP (NT-
proBNP) are diagnostic and prognostic biomarkers of
heart failure and are also increased in patients with
chronic kidney disease (CKD). We examined the rele-
vance of BNP and NT-proBNP as predictors of CKD
progression.
Methods: Of 227 nondiabetic patients with mild-to-
moderate renal insufficiency, 177 patients ages 18–65
years were followed in a prospective multicenter cohort
study for a period of <7 years. CKD progression was
assessed by recording renal endpoints, defined as dou-
bling of baseline serum creatinine or end-stage renal
disease (ESRD) requiring renal replacement therapy.
Results: BNP and NT-proBNP were significantly higher
among 65 patients who reached the combined renal
endpoint than among the 112 who did not [median
(interquartile range) 61 (27–98) ng/L vs 39 (20–70) ng/L,
P  0.023, for BNP; 320 (117–745) ng/L vs 84 (44–176)
ng/L, P <0.001, for NT-proBNP)]. Each increment of 1
SD in log-transformed BNP and NT-proBNP increased
the risk of CKD progression by hazard ratios of 1.38
(95% CI 1.09–1.76, P  0.009) and 2.28 (1.76–2.95, P
<0.001), respectively. After adjustment for other estab-
lished prognostic factors of CKD progression, NT-
proBNP but not BNP remained a significant indepen-
dent predictor of the combined renal endpoint.
Conclusions: Increased BNP and NT-proBNP concen-
trations indicate an increased risk for accelerated pro-
gression of CKD to ESRD and may prove to be valuable
biomarkers for the assessment of prognosis in patients
with CKD.
© 2007 American Association for Clinical Chemistry
Chronic kidney disease (CKD),7 an increasingly prevalent
condition in Western societies, is frequently associated
with a progressive decrease in glomerular filtration rate
(GFR), leading to end-stage renal disease (ESRD), for
which renal replacement therapy is required (1 ). Al-
though this decrease in GFR is fairly constant in the
individual patient, there are significant interindividual
differences in the rate of decrease. Established risk factors
for CKD progression include type of renal disease; non-
modifiable patient characteristics such as ethnic back-
1 Institute of Clinical Chemistry, University Hospital Zurich, Zurich,
Switzerland.
2 Division of Genetic Epidemiology, Department of Medical Genetics,
Molecular and Clinical Pharmacology, Innsbruck Medical University, Inns-
bruck, Austria.
3 Department of Internal Medicine, Division of Nephrology, Ruprecht-
Karls-University, Heidelberg, Germany.
4 Functional Genomics Center, University of Zu¨rich and ETH Zu¨rich,
Zu¨rich, Switzerland.
5 Division of Nephrology, Department of Internal Medicine, Hannover
Medical School, Hannover, Germany.
6 Innsbruck University Hospital, Department of Clinical Nephrology,
Innsbruck, Austria.
* Address correspondence to this author at: Institute for Clinical Chemis-
try, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Fax 41-1-255-4590; e-mail arnold.voneckardstein@usz.ch.
Received November 15, 2006; accepted April 5, 2007.
Previously published online at DOI: 10.1373/clinchem.2006.083170
7 Nonstandard abbreviations: CKD, chronic kidney disease; GFR, glomer-
ular filtration rate; ESRD, end-stage renal disease; BNP, B-type natriuretic
peptide; NT-proBNP, N-terminal proBNP; CHF, congestive heart failure; LVD,
left ventricular dysfunction; IQR, interquartile range; BMI, body mass index;
RAAS, renin-angiotensin-aldosterone system.
Clinical Chemistry 53:7
1264–1272 (2007) Proteomics and
Protein Markers
1264
ground, sex, age, and baseline kidney function; and
modifiable risk factors including blood pressure, glycemic
control in diabetes, degree of proteinuria, serum albumin
concentration, smoking, dyslipidemia, and anemia (2, 3).
B-type natriuretic peptide (BNP) and N-terminal
proBNP (NT-proBNP) concentrations are associated with
the severity and prognosis of congestive heart failure
(CHF) and left ventricular dysfunction (LVD) and have
emerged as useful biochemical markers for the diagnosis
and prognosis of heart diseases (4–8). Plasma concentra-
tions of NT-proBNP and BNP are also increased in
patients with impaired kidney function and have been
significantly correlated with the estimated GFR in pa-
tients with and without CHF (9–11). The mechanisms
underlying these associations and correlations are not
well understood but are postulated to reflect impaired
renal clearance of natriuretic peptides. We hypothesize
that increased BNP and NT-proBNP plasma concentra-
tions reflect the homeostatic response of the heart to
disturbed renal function in the context of a cardiorenal
syndrome, which is suggested to amplify progression of
both CHF and CKD (12 ). We investigated, in a prospec-
tive study, whether increased BNP and NT-proBNP con-
centrations predict the progression of disease in patients
with mild or moderate chronic nondiabetic kidney
disease.
Patients and Methods
study population
In 1997, 227 white male or female patients with primary
CKD and mild-to-moderate impaired renal function were
recruited from 8 nephrology departments in Germany,
Austria, and South Tyrol (Italy) (13, 14). Study patients
(ages 18–65 years at the time of recruitment) had nondi-
abetic CKD and had visited the outpatient department at
least once during the preceding year. Exclusion criteria
were serum creatinine 6 mg/dL (531 mol/L); malig-
nancy; liver, thyroid, or infectious disease; nephrotic
syndrome (defined as daily proteinuria 3.5 g/1.73 m2);
organ transplantation; immunosuppressive treatment; al-
lergy to ionic contrast media; and pregnancy. All patients
were recruited by a single investigator. The study was
approved by the institutional ethics committees, and all
participants gave their informed consent before inclusion
in the study.
Of the primary cohort of 227 patients, 177 could be
followed prospectively over a period of 84 months.
Patients received regular follow-up care in the outpatient
ward, and defined endpoints—doubling of baseline se-
rum creatinine or ESRD with the need of renal replace-
ment therapy—were reported to the study coordinating
center. Fifty patients (22%) were lost to follow-up because
they moved or were not referred by their usual doctors to
the study centers. Patients lost to follow-up had signifi-
cantly better renal function but did not differ significantly
in sex or age (14 ).
blood sampling and measurements
At baseline, we collected blood samples for the prepara-
tion of serum and EDTA plasma in plastic tubes after
patients had fasted overnight for 12 h. The samples
were centrifuged immediately at 1500g and 4 °C for 10
min. Aliquots of the supernatants were stored at 80 °C.
GFR was assessed by the iohexol method as described
(14, 15). In 2004, frozen plasma samples were used to
measure BNP and NT-proBNP in the Institute of Clinical
Chemistry of the University Hospital Zurich on the
AxSYM System (Abbott Laboratories; CV 10% at con-
centrations of 90 to 2000 ng/L) and the Roche Diagnostics
Modular Analytics E170 system (CV 4% at concentra-
tions of 30 to 5000 ng/L). The lower limits of detection are
15 ng/L for the BNP assay and 5 ng/L for the human
NT-proBNP assay. For statistical analyses, BNP concen-
trations below the detection limit (n  44) were assigned
a value of 15 ng/L. All measurements were performed by
a single technician who was unaware of the clinical
information of the patients.
The clinical laboratories of the local hospitals where the
patients were recruited and followed up measured
plasma concentrations of creatinine in fresh samples by
use of the Jaffe methods of various manufacturers. Al-
though these measurements were not yet fully standard-
ized, they allowed assessment of the endpoint “doubling
of creatinine”, because each patient was monitored by the
same laboratory and each laboratory maintained its
method throughout the study period.
statistical analysis
Continuous data are presented as median and range or
interquartile range (IQR). Discrete data are given as
counts and percentages. We compared categorical vari-
ables by 2 test. We used the Mann–Whitney U-test and
Kruskal–Wallis analysis for comparisons of continuous
data and the nonparametric Jonckheere–Terpstra test for
analyzing trends in the relationship between GFR and
BNP or NT-proBNP.
Data with skewed distributions [BNP, NT-proBNP,
body mass index (BMI), degree of proteinuria, GFR, total
cholesterol, HDL-cholesterol, triglycerides, and diastolic
and systolic blood pressure] were normalized by natural
logarithmic transformation. This procedure decreased the
skewness to values close to 0 for all indicated parameters.
We used Spearman rank regression analysis to assess
correlations of GFR with BNP or NT-proBNP plasma
concentrations.
We performed univariate Cox proportional hazards
analysis to identify predictors of the combined and iso-
lated renal endpoints. We constructed multivariate Cox
proportional hazard models to assess the independent
prognostic roles of BNP and NT-proBNP in addition to
known confounders of CKD progression (see Results). We
used ROC analysis to determine optimal cutoff values for
the analysis of BNP and NT-proBNP by Kaplan Meier
time-to-event analysis. We assessed the equality of sur-
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vival distributions by log-rank test. For the analyses that
used doubling of baseline serum creatinine as an isolated
endpoint, patients who reached ESRD at an earlier time
point were excluded. For all tests, P0.05 was considered
to be statistically significant. Data were processed and
analyzed with SPSS 12.0.1 software (SPSS).
Results
patients
The primary causes of CKDwere glomerulonephritis (n
97, 43%), polycystic kidney disease (n  37, 16%), inter-
stitial nephritis (n  24, 11%), other types of renal disease
(n  43, 19%), and unknown (n  26, 12%). Twenty-eight
patients had a history of cardiovascular events [myocar-
dial infarction, aortocoronary bypass, percutaneous trans-
luminal coronary angioplasty, angiographically verified
stenosis of the coronary arteries, stroke, or a symptomatic
stenosis of the peripheral arterial vessels (carotid, aorto-
iliac, or femoral arteries)].
Baseline clinical characteristics of 227 patients with
nondiabetic CKD are shown in Table 1. Patients were
classified into 4 groups according to baseline stages of
GFR as defined in the clinical practice guidelines of the
National Kidney Foundation (2 ). In addition to expected
increases in plasma concentrations of creatinine and urea
(P 0.001), decreasing GFR was significantly associated
with the need for antihypertensive treatment and increas-
ing protein excretion (P 0.004). Notably, BMI, systolic or
diastolic blood pressure, and previous cardiovascular
events did not differ significantly between groups.
association of bnp and nt-proBNP plasma
concentrations with renal function
Baseline BNP and NT-proBNP concentrations were mea-
sured in 225 and 222 patients of the study cohort, respec-
tively, and ranged from 15 to 445 ng/L [median (IQR)
41 (20–82) ng/L] and from 7 to 3950 ng/L [105 (43–283)
ng/L], respectively. Baseline BNP and NT-proBNP con-
centrations correlated with GFR (Spearman correlation
coefficients Rs  0.168, P  0.011, and Rs  0.609, P
0.001, respectively). Both BNP and NT-proBNP plasma
concentrations were progressively higher in patients with
Table 1. Baseline clinical and laboratory data of patients with CKD stratified into 4 groups according to baseline GFR.a
Group
GFR >90 mL  min1
 (1.73 m2)1
GFR 60–89 mL  min1
 (1.73 m2)1
GFR 30–59 mL  min1
 (1.73 m2)1
GFR <30 mL  min1
 (1.73 m2)1 All patients
n 72 49 63 43 227
Median age,
years (range)
39 (18–64) 49 (19–63) 48 (20–65) 56 (29–65) 48 (18–65)b
Sex, n (%)
Female 22 (31) 15 (31) 19 (30) 17 (40) 73 (32)
Male 50 (69) 34 (69) 44 (70) 26 (60) 154 (68)
Prior cardiovascular
events, n (%)
5 (7) 8 (16) 9 (14) 6 (14) 28 (12)
Median BMI,
kg/m2 (IQR)
24.1 (21.6–26.9) 25.4 (23.2–28.2) 25.0 (23.2–27.4) 24.8 (23.2–28.7) 24.6 (22.7–27.4)
Smoking status, n (%)
Nonsmoker 36 (50) 26 (53) 35 (56) 24 (56) 121 (53)
Former smoker 18 (25) 12 (25) 17 (27) 10 (23) 57 (25)
Current smoker 18 (25) 11 (22) 11 (17) 9 (21) 49 (22)
Median creatinine,
mol/L (IQR)
98 (84–115) 126 (110–150) 193 (150–248) 309 (241–408) 142b (1061–210)
Median urea,
mmol/L (IQR)
5.32 (3.50–6.96) 6.66 (5.26–8.41) 11.66 (7.49–15.98) 14.07c (12.95–20.48) 7.66b,c (5.33–13.35)
Median proteinuria,
g/24 h (IQR)
0.36 (0.13–0.82) 0.57 (0.16–1.93) 0.80 (0.27–1.83) 0.89 (0.36–1.52) 0.56d (0.18–1.42)
Median systolic blood
pressure,
mmHg (IQR)
130.0 (120.0–141.5) 135.0 (120.0–157.5) 140.0 (123.0–150.0) 140.0 (122.0–152.0) 135.0 (120.0–150.0)
Median diastolic blood
pressure,
mmHg (IQR)
83.0 (73.0–90.75) 85.0 (80.0–100.0) 90.0 (80.0–99.0) 90.0 (80.0–95.0) 86.0e (80.0–95.0)
Antihypertensive
medication, n (%)
41 (57) 41 (84) 57 (90) 40 (93) 179 (79)b
Lipid-lowering agents,
n (%)
10 (14) 11 (22) 18 (29) 6 (14) 45 (20)
a GFR was measured by iohexol clearance. To convert values for creatinine to mol/L, multiply by 88.5. To convert values for urea to mmol/L, multiply by 0.116.
b P value provided for global comparisons: P 0.001.
c Urea value is missing for 1 individual.
d P value provided for global comparisons: P 0.01.
e P value provided for global comparisons: P 0.05.
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progressively more advanced stages of CKD as defined by
the Disease Outcomes Quality Initiative of the National
Kidney Foundation (2 ). As evident from the box-whisker
plots in Fig. 1, the increase in NT-proBNP concentrations
was more pronounced (medians ranged from 39 ng/L in
group 1 to 456 ng/L in group 4, P 0.001 for both
Kruskal–Wallis test and Jonckheere–Terpstra test) than
the increase of BNP concentrations (medians ranged from
34 ng/L in group 1 to 57 ng/L in group 4; Kruskal Wallis
test P  0.019 and Jonckheere–Terpstra test P  0.002 for
trend). When BNP concentrations among individual
groups were compared, the difference was significant
only between groups 1 and 3 (P  0.046) and between
groups 1 and 4 (P  0.003). In contrast, NT-proBNP
concentrations differed significantly between groups 1
and 2 (P0.001) and became even more pronounced with
a further decrease in renal function. Thus even a moderate
decrease of renal function was associated with increased
NT-proBNP concentrations.
bnp and nt-proBNP as predictors of ckd
progression
Of the 177 patients available for follow-up, 65 reached at
least 1 of the predefined renal endpoints: 29 patients
progressed to ESRD requiring renal replacement therapy,
and 36 patients experienced a doubling of baseline serum
creatinine without needing ESRD. BNP and NT-proBNP
concentrations were significantly higher among patients
who reached both renal endpoints than among those who
did not [median (IQR) 61 (27–98) ng/L vs 39 (20–70)
ng/L, P  0.023, for BNP; 320 (117–745) ng/L vs 84
(44–176) ng/L, P 0.001, for NT-proBNP]. Patients were
stratified into 2 groups by BNP and NT-proBNP concen-
trations above and below the optimal cutoff concentra-
tions suggested by ROC analysis according to the com-
bined endpoint, namely 56 ng/L for BNP [area under the
ROC curve (95% CI) 0.603 (0.515–0.692), P  0.025] and
213 ng/L for NT-proBNP [0.758 (0.681–0.835), P 0.001;
Fig. 2]. Patients with BNP above the cutoff had lower GFR
than those with BNP below the cutoff (Table 2). A
significantly higher proportion of patients with higher
BNP concentrations reached both endpoints vs patients
with BNP below the cutoff (48.6% vs 28.6%, P  0.007).
Compared with patients with NT-proBNP concentrations
below the cutoff, those with NT-proBNP concentrations
above the cutoff were older and had higher creatinine and
urea concentrations, lower GFR, and higher systolic blood
pressure (Table 2). Furthermore, a markedly higher pro-
portion of patients with NT-proBNP concentrations above
the cutoff reached at least 1 of the predefined renal
endpoints (66% vs 19%, P 0.001).
Kaplan–Meier analysis was performed to compare the
strata of BNP or NT-proBNP concentrations for the time
to reach 1 or both endpoints (Fig. 3). The corresponding
log-rank test revealed a significant difference for both
parameters with respect to combined endpoints (P 
0.003 for BNP and P 0.001 for NT-proBNP). The unad-
justed hazard ratios (95% CI) for the combined renal
Fig. 1. Plasma concentrations of BNP
and NT-proBNP in relation to CKD
stages (Disease Outcomes Quality Ini-
tiative of the National Kidney Founda-
tion) based on GFR determined by
iohexol clearance.
The horizontal lines inside the box indicate
the respective median, the box spans the
IQR, and the whiskers represent the largest
and smallest values that are not outliers.
Values given in brackets reflect P values for
differences among individual subgroups.
Fig. 2. ROC analysis of BNP and NT-proBNP as predictors of the
combined renal endpoint of CKD progression.
Arrows indicate the localization of the optimal cutoff concentrations for BNP (56
ng/L; sensitivity, 0.532; specificity, 0.676) and NT-proBNP (213 ng/L; sensitiv-
ity, 0.661; specificity, 0.811).
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outcome by BNP and NT-proBNP above the cutoff were
2.09 (1.27–3.44), P  0.004, for BNP and 5.16 (3.01–8.82), P
0.001, for NT-proBNP. The same was true for the
isolated clinical endpoint ESRD: during the follow-up,
both BNP and NT-proBNP cutoff values significantly
discriminated patients reaching the endpoint from those
who did not [log-rank test P  0.004 for BNP and P
0.001 for NT-proBNP; hazard ratio (95% CI) 2.90 (1.37–
6.15), P  0.005, for BNP and 9.17 (3.71–22.69), P 0.001,
for NT-proBNP above the respective cutoff]. For the
isolated endpoint of doubling of serum creatinine, the
discriminating power was less pronounced, reaching sta-
tistical significance for NT-proBNP but not for BNP
[log-rank test P 0.001 for NT-proBNP and P  0.11 for
BNP, hazard ratio (95% CI) 4.08 (2.04–8.16), P 0.001, for
NT–proBNP and 1.72 (0.88–3.38), P  0.12, for BNP].
The results of the univariate Cox regression analysis
for BNP and NT-proBNP were similar when the variables
were analyzed as continuous covariates. Both BNP and
NT-proBNP were identified as predictors of the combined
renal endpoints (Table 3). After stratification for the single
endpoints, univariate Cox regression analysis revealed
that both BNP and NT-proBNP are associated with up-
coming need for renal replacement therapy, whereas only
NT-proBNP emerged as a significant predictor of a dou-
bling of creatinine during the follow-up period (Table 3).
In multivariate Cox proportional hazards analysis of
the combined renal outcomes (Table 3), adjustment for sex
and age led to a slightly increased hazard ratio for
NT-proBNP but did not substantially influence the pre-
dictive value of BNP. After adjustment for GFR and
further covariates known to be related to the progression
of CKD (BMI, plasma albumin, hemoglobin, degree of
proteinuria, diastolic blood pressure, systolic blood pres-
sure, total cholesterol, HDL-cholesterol, triglycerides,
smoking, use of antihypertensive medication, prior car-
diovascular events), the association of NT-proBNP, but
not that of BNP, with the combined renal outcome re-
mained significant (hazard ratio 1.91, 95% CI 1.22–3.01,
P 0.005, for NT-proBNP). An increase of NT-proBNP by
1 SD nearly doubled the risk of progressing to 1 of the
predefined renal endpoints during the follow-up. Adjust-
ment for age and sex exerted a minor effect on the
strength of the associations of NT-proBNP with the iso-
lated renal endpoints in multivariate Cox regression anal-
ysis but showed no effect for BNP. Further adjustment for
traditional risk factors as indicated in the legend of Table
3 identified NT-proBNP, but not BNP, as an independent
predictor of both isolated endpoints [hazard ratio (95%
CI) 1.90 (1.03–3.49), P 0.039, for the doubling of baseline
serum creatinine; 2.32 (1.05–5.14), P  0.038, for ESRF
requiring dialysis therapy].
association of bnp and nt-proBNP with
cardiovascular events in the past and during
follow-up
Twenty-seven patients with a past cardiovascular event at
baseline were more frequently male (16% vs 5%), were
Table 2. Baseline clinical characteristics according to BNP and NT-proBNP values above and below the cutoff.a
BNP NT-proBNP
<56 ng/L >56 ng/L P value <213 ng/L >213 ng/L P value
n 105 70 112 62
Median age, years (range) 48 (20–64) 51 (18–65) NS 44.5 (18–64) 54 (23–65) 0.001
Sex NS NS
Female 33 (31) 26 (37) 33 (30) 26 (42)
Male 72 (69) 44 (63) 79 (70) 36 (58)
GFR, mL  min1  (1.73
m2)1
62.8 (38.5–92.7) 46.5 (29.0–77.9) 0.032 77.0 (47.1–101.4) 36.6 (19.0–47.2) 0.001
Creatinine, mol/L 144 (108–201) 179 (122–290) NS 124 (102–164) 253 (177–347) 0.001
Urea, mmol/L 8.74 (5.41–13.4) 9.16 (6.23–14.07)b NS 7.66 (5.16–10.54) 13.49 (7.24–17.95)b 0.001
Proteinuria, g/24 h 0.69 (0.17–1.41) 0.81 (0.31–1.79) NS 0.56 (0.16–1.37) 1.00 (0.34–1.93) 0.023
Systolic blood pressure,
mmHg
134.0 (120.0–150.0) 138.0 (120.0–153.0) NS 130.0 (120.0–149.25) 140.0 (125.0–157.0) 0.011
Diastolic blood pressure,
mmHg
87.0 (80.0–95.0) 86.0 (77.8–95.0) NS 85.0 (76.25–93.75) 89.0 (80.0–95.25) NS
CKD stage NS 0.001
1 29 (28) 13 (19) 42 (38) 1 (2)
2 26 (25) 13 (19) 31 (28) 8 (13)
3 32 (30) 25 (36) 30 (27) 25 (40)
4 18 (17) 19 (27) 9 (8) 28 (45)
Both endpoints reached,
n (%)
30 (29) 34 (49) 0.007 21 (19) 41 (66) 0.001
a Values for continuous variables are median (IQR) if not otherwise indicated. Discrete data are given as n (%). Cutoffs for BNP (56 ng/L) and NT-proBNP (213 ng/L)
were determined by ROC analysis. To convert values for creatinine to mg/dL, divide by 88.4. To convert values for urea to mg/dL, divide by 0.1665.
b Urea value is missing for one individual.
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Fig. 3. Kaplan–Meier survival curves of patients with
mild or moderate CKD according to BNP and NT-
proBNP and different renal endpoints.
Data were stratified according to cutoffs for BNP (56 ng/L)
and NT-proBNP (213 ng/L), as well as both (A) and single (B
and C) renal endpoints.
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older [median (range) 56 (39–62) years vs 47 (18–65)
years], and presented with higher NT-proBNP concentra-
tions [median (IQR) 199 (86–549) ng/L vs 91 (39–263)
ng/L]. Other factors, including BNP and GFR, did not
differ significantly. Ten patients experienced a major
cardiovascular event and 3 patients died during the 7
years of follow-up. These numbers were too low to allow
calculation of reliable estimates for incident events by Cox
regression analysis. Median (range) concentrations of
BNP and NT-proBNP in the 10 patients with cardiovas-
cular events were 39 (15–294) ng/L and 148 (20–3606)
ng/L, respectively.
Discussion
We show that BNP and NT-proBNP plasma concentra-
tions are associated with the progression of renal failure
in patients with primary, nondiabetic CKD. BNP and
NT-proBNP are both released from the heart in response
to wall stretch induced by volume or pressure overload
and have been introduced into the clinical routine as
valuable diagnostic and prognostic markers of CHF and
LVD (4–8, 16). In addition, BNP and NT-proBNP plasma
concentrations have been found to be increased in pa-
tients with impaired renal function (10, 17). In our study,
in accordance with published data (9–11, 16), median
BNP and NT-proBNP concentrations increased in parallel
with decreasing renal function. Hence, even a moderate
restriction of GFR was associated with a significant in-
crease of NT-proBNP values.
To date, the increase of BNP and NT-proBNP concen-
trations in patients with impaired renal function has been
considered an unwanted confounder in the diagnostics of
CHF. Moreover, the reason for increased BNP and NT-
proBNP concentrations in patients with impaired renal
function has not been clarified. The most frequently used
explanation is renal retention of both BNP and NT-
proBNP. In accordance with this explanation are the
strong correlations of GFR with BNP and NT-proBNP
concentrations. Surprisingly, increased rather than de-
creased urinary concentrations of BNP have been found in
patients with renal impairment compared with healthy
controls (18 ). Furthermore, urinary NT-proBNP was sig-
nificantly correlated with NT-proBNP and creatinine con-
centrations in plasma of healthy individuals (19 ). These
inverse correlations between renal function and urinary
BNP or NT-proBNP indicate that renal retention is not the
only reason for increased plasma concentrations of BNP
and NT-proBNP in patients with impaired renal function.
Increased concentrations in such patients may arise rather
from an increased release of both BNP and NT-proBNP
into the circulation.
In the multivariate Cox regression analysis, NT-
proBNP but not BNP remained a significant predictor of
accelerated progression of CKD to 1 or both endpoints
even after adjustment for GFR and further factors associ-
ated with progression of CKD. Furthermore, in patients
with CKD both estimated GFR and left ventricular mass
have been described to be independent confounders of
BNP and NT-proBNP concentrations (20 ). Because BNPs
are released from cardiomyocytes, the progressive in-
crease of BNP and NT-proBNP with decreasing renal
function may reflect cardiac involvement in CKD patients
in terms of a cardiorenal syndrome. Because no other data
on cardiac function than BNP and NT-proBNP values are
available for our patients, this model remains to be shown
by future studies. However, prevalences of LVD and CHF
are increased in patients with renal impairment, and the
prevalence of renal dysfunction is increased in patients
with cardiac dysfunction (10, 21, 22). This coincidence
and the correlation of severity of renal impairment with
LVD and CHF point to a mutual relationship of renal and
cardiac impairment.
Progression of CKD is associated with impaired salt
regulation and extracellular fluid volume expansion (23 ).
Therefore, the inverse relationship between GFR and
plasma BNP or NT-proBNP concentrations may reflect an
increased volume load of the heart as a consequence of
volume expansion due to restricted GFR. The increased
activity of the renin-angiotensin-aldosterone system
(RAAS) in CKD and even in very early, clinically asymp-
Table 3. BNP and NT-proBNP as predictors of renal endpoints.a
Analysis BNP NT-proBNP
Both endpoints Univariate analysis 1.38 (1.09–1.76), 0.009 2.28 (1.76–2.95), 0.001
Adjusted for sex and age 1.35 (1.06–1.72), 0.015 2.43 (1.82–3.25), 0.001
Adjusted for further variablesb 1.19 (0.89–1.59), 0.25 1.91 (1.22–3.01), 0.005
Doubling of creatinine Univariate analysis 1.23 (0.88–1.73), 0.22 2.01 (1.39–2.91), 0.001
Adjusted for sex and age 1.23 (0.88–1.72), 0.23 2.27 (1.51–3.41), 0.001
Adjusted for further variablesb 1.23 (0.80–1.90), 0.34 1.90 (1.03–3.49), 0.039
Dialysis Univariate analysis 1.65 (1.16–2.34), 0.006 3.07 (2.09–4.53), 0.001
Adjusted for sex and age 1.61 (1.12–2.32), 0.010 3.15 (2.03–4.91), 0.001
Adjusted for further variablesb 1.22 (0.77–1.93), 0.40 2.32 (1.05–5.14), 0.038
a Data are hazard ratio (95% CI), P value. Hazard ratios were determined by univariate and multivariate Cox proportional hazard analysis and are indicated for each
increment of 1 SD in the log-transformed BNP (1 SD  0.817) and NT-proBNP (1 SD  1.304) values, respectively.
b Adjusted for sex, age, BMI, plasma albumin, hemoglobin, degree of proteinuria, GFR, diastolic blood pressure, systolic blood pressure, total cholesterol,
HDL-cholesterol, triglycerides, smoking, use of antihypertensive medication, and prior cardiovascular events.
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tomatic stages of CHF may influence BNP and NT-
proBNP plasma concentrations. Because BNP is induced
by angiotensin II in cardiac myocytes (24 ) and counteracts
the water and sodium retention caused by activated
RAAS and suppresses aldosterone (25 ), increased concen-
trations of BNP and NT-proBNP in renal failure and their
association with poor renal prognosis might reflect the
activation of the RAAS, which is supposed to promote
CKD. Thus, from a physiological perspective, increased
concentrations of either BNP or NT-proBNP in renal
failure reflect not only impaired glomerular filtration but
also a counterregulatory response of the heart to changes
in hemodynamics and water homeostasis. BNP and NT-
proBNP may hence be considered markers of the cardio-
renal syndrome, a pathophysiological condition that am-
plifies the progression of both cardiac and renal failure,
leading to ESRD and CHF (12 ). Thus, BNP and NT-
proBNP have recently evolved as markers for the diagno-
sis and prognosis of CHF in CKD patients (9, 11, 26–28).
In addition, a small study (28 ) and the present study
identified BNP and NT-proBNP as prognostic markers for
the progression of CKD.
Our data demonstrate that increased BNP and NT-
proBNP concentrations are associated with accelerated
progression of mild and moderate primary CKD to renal
endpoints. After adjustment for several factors known to
be associated with the progression of CKD, however, only
NT-proBNP emerged as an independent predictor of one
or both renal endpoints. NT-proBNP, therefore, provides
prognostic information in addition to the established risk
markers of progression of CKD. Although NT-proBNP is
not the biologically active peptide, it appears to be the
more suitable prognostic measure to estimate the risk of
CKD progression compared with active BNP. This may be
due to the longer half-life of NT-proBNP compared with
BNP (120 vs 22 min) (29 ), so that NT-proBNP more stably
reflects changes in hemodynamics. In addition, the role of
BNP as a prognostic biomarker of CKD progression might
be compromised because 20% of patients presented with
BNP concentrations below the detection limit (NT-
proBNP was detectable in all cases); however, the optimal
cutoff of 56 ng/mL is well above the detection limit of
15 ng/mL.
Our study has 3 major limitations that must be ad-
dressed in further studies. First, because the time of
follow-up varied considerably among patients who
reached neither of the renal endpoints, our study design is
not appropriate to define conclusive cutoffs for stratifying
the risk of reaching ESRD within defined time intervals.
Future studies involving sequential measurements of
BNP and NT-proBNP are needed to define reliable cutoff
values. Second, our data are restricted to nondiabetic
patients who were only 18–65 years old at the time of
inclusion in the study. It will be important to show
whether our observations are also valid in older patients
and patients with diabetes. Third, we have no data on the
structure and function of the heart, either at baseline or
during follow-up. These data are needed to unravel
whether natriuretic peptides are associated with CKD
progression independently of subclinical CHF and
whether increased BNP and NT-proBNP reflect structural
heart disease or a homeostatic response to water and salt
retention as well as activated neurohormonal systems.
In conclusion, increased concentrations of BNP and NT-
proBNP indicate an increased risk for accelerated progres-
sion of mild or moderate CKD ultimately to ESRD.
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